T. Rowe Price Investment Management, Inc. Crinetics Pharmaceuticals, Inc. Transaction History
T. Rowe Price Investment Management, Inc.
- $151 Billion
- Q1 2025
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 689,265 shares of CRNX stock, worth $21.5 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
689,265
Previous 1,002,882
31.27%
Holding current value
$21.5 Million
Previous $51.3 Million
54.92%
% of portfolio
0.02%
Previous 0.03%
Shares
9 transactions
Others Institutions Holding CRNX
# of Institutions
235Shares Held
87MCall Options Held
40KPut Options Held
162K-
Vanguard Group Inc Valley Forge, PA9.31MShares$291 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA6.89MShares$215 Million0.05% of portfolio
-
Driehaus Capital Management LLC Chicago, IL6.24MShares$195 Million2.28% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$194 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.11MShares$160 Million0.02% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $1.68B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...